NCT07213089 - Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers | Biotech Hunter

Enrollment

290

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

April 4, 2022

Study Completion Date

May 12, 2022

Conditions

Pertussis Whooping Cough

Interventions

BIOLOGICAL

Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine

A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml will be given by intramuscularly at Day 0

BIOLOGICAL

Licensed DTaP

A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml. will be given by intramuscular as at Day 0

Trial Locations (3)

Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University, Bangkok

Kamphaengphet Hospital, Kamphaeng Phet

Phaholpolpayuhasena Hospital, Kanchanaburi

All Listed Sponsors

collaborator

National Science and Technology Development Agency, Thailand

OTHER_GOV

collaborator

Mahidol University

OTHER

lead

BioNet-Asia Co., Ltd.

INDUSTRY